ANTIPARASITIC RESISTANCE: UPDATE ON THE PLANNED ACTIVITIES
Kuala Lumpur (Malaysia) 14-16 January 2020

Dr Mária Szabó
OIE AMR & Veterinary Products Department
Paris, France
Currently no OIE standards or guidelines related to antiparasitic products

Feedback from the 4th and 5th cycle OIE Focal Point training seminars on veterinary products

Current situation based on the feedback received

Future Plan and Actions
Currently no OIE standards and guidelines on antiparasitic products

- Trypanocides ... Specific Monograph


(slide from the previous seminars)
Feedback from the 4th and 5th Cycle of the OIE Focal Point training seminars

Antiparasitic drugs and challenges of antiparasitic resistance were first addressed at the 4th Cycle of the Seminar, in Entebbe, Uganda in 2015.

Strong support received from the attendees that the OIE needs to consider publishing standards for antiparasitic drugs.

This view was repeated during the OIE Regional Seminars for Veterinary Products for Asia (Tokyo, March 2016), Europe (Budapest, October 2016) and Middle East (Beirut, November 2017).

As a result: The subject of antiparasitic drugs and related challenges was included into the 5th Cycle training seminar in order to seek views in the interactive panel discussion.
Feedback from the 4th and 5th Cycle of the OIE Focal Point training seminars

Interactive panel discussion intended to find answers for 2 main questions in the 5th Cycle:

<table>
<thead>
<tr>
<th>Do we need OIE standards and guidelines on prudent and responsible use of antiparasitics?</th>
<th>Is it relevant for Africa, Asia, the Americas, Europe and the Middle East?</th>
</tr>
</thead>
</table>

Feedback from the 5th Cycle of the OIE Focal Point training seminars

- All training seminars expressed a deep-rooted desire and interest working together to tackle the antiparasitic resistance

The latest seminar, which took place for the Region of Americas, from 1-3 August Tecámac (Mexico) 2018, concluded that urgent actions, led by the OIE, should be considered.
Current situation

1. There is a lack of effective drugs and resistance to many antiparasitics, especially to trypanocides, ascarides and anthelmintic resistance remain challenges to overcome.

2. There are many generic products which have been used for more than 50 years, but not enough new ‘quality’ drugs available.

3. Poor quality products are on the markets, (substandard and falsified products); exposure of the sub-therapeutic doses, low concentration of active ingredient.

4. Antiparasitic drug residues in the environment (e.g. ivermectin and toltrazuril).

5. Residues in the food due to absence of appropriate withdrawal periods.

6. Lack of legislation for appropriate authorization of veterinary medicinal products in many countries.
Current situation

There are some proposed strategies to delay or minimise the development of resistance were similar across drug product classes:

These strategies include ensuring

- accurate diagnosis, animal weights, and dosage
- proper label instructions for preparation and use of the product,
- selectively treating only animals that are clinically ill when possible,
- strategic use of antiparasitic drugs in an integrated parasite management plan when animals are at high risk for disease (e.g. young animals or high challenge).

Further, in some cases, animals that have innate resistance to the parasite species may be better suited in those geographic regions where the disease is prevalent (e.g. trypanotolerant breeds of cattle)

Multiple initiatives intended to monitor and address the problem of resistance were presented
Update from the field concerning antiparasitic resistance

Feedback from the 5th Cycle of the OIE Focal Point training seminars on veterinary products

The ‘Concept Note’ was endorsed by the Hierarchy 2019

The experts from different Regions will work on a publication on a Responsible and Prudent Use of Antiparasitics document which would be subject to endorsements by the OIE Director General and Scientific Commission for Animal Diseases (SCAD).

The OIE, worked and will work closely its Collaborating Centers, and this subject will be lead by the Veterinary Medicine-Food and Drug Administration (CVM-FDA), who intends to continue this work.
Future Plan and Actions

- FPs will be regularly informed on the progress made.
- The publication could become the basis for the OIE Standards or Guideline(s) for prudent and responsible guideline for antiparasitics if warranted.
- Consider a future issue of the Scientific and Technical Review dedicated to parasite management and antiparasitic resistance.
Thank you for your attention!

Dr Mária Szabó
Antimicrobial Resistance and Veterinary Products Department
Paris, France
m.szabo@oie.int

WORLD ORGANISATION FOR ANIMAL HEALTH
Protecting animals, preserving our future